vs
Cencora（COR）与Meta Platforms（META）财务数据对比。点击上方公司名可切换其他公司
Cencora的季度营收约是Meta Platforms的1.4倍（$85.9B vs $59.9B），Meta Platforms净利率更高（38.0% vs 0.7%，领先37.4%），Meta Platforms同比增速更快（23.8% vs 13.9%），Meta Platforms自由现金流更多（$14.8B vs $-2.4B），过去两年Meta Platforms的营收复合增速更高（28.2% vs 12.1%）
Cencora前身为美国医药企业美源伯根（AmerisourceBergen），2001年由Bergen Brunswig与AmeriSource合并成立，2023年正式更为现名。公司主营药品批发分销及合同研究服务，是全球规模最大的医药行业企业之一，分销产品覆盖仿制药、非处方医疗用品、家用医疗耗材及设备等。
Meta Platforms是总部位于美国加利福尼亚州门洛帕克的跨国科技巨头，属于全球头部科技企业阵营。旗下运营Facebook、Instagram、WhatsApp、Messenger、Threads等多款知名社交媒体及通讯服务，同时开展自有及第三方站点广告业务，2023年广告收入占其总营收的97.8%。
COR vs META — 直观对比
营收规模更大
COR
是对方的1.4倍
$59.9B
营收增速更快
META
高出9.9%
13.9%
净利率更高
META
高出37.4%
0.7%
自由现金流更多
META
多$17.3B
$-2.4B
两年增速更快
META
近两年复合增速
12.1%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $85.9B | $59.9B |
| 净利润 | $559.6M | $22.8B |
| 毛利率 | 3.6% | 81.8% |
| 营业利润率 | 0.9% | 41.3% |
| 净利率 | 0.7% | 38.0% |
| 营收同比 | 13.9% | 23.8% |
| 净利润同比 | -22.0% | 9.3% |
| 每股收益（稀释后） | $2.87 | $8.87 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CORMETA
| Q4 25 | $85.9B | $59.9B | ||
| Q3 25 | $83.7B | $51.2B | ||
| Q2 25 | $80.7B | $47.5B | ||
| Q1 25 | $75.5B | $42.3B | ||
| Q4 24 | $81.5B | $48.4B | ||
| Q3 24 | $79.1B | $40.6B | ||
| Q2 24 | $74.2B | $39.1B | ||
| Q1 24 | $68.4B | $36.5B |
净利润CORMETA
| Q4 25 | $559.6M | $22.8B | ||
| Q3 25 | $-339.7M | $2.7B | ||
| Q2 25 | $687.4M | $18.3B | ||
| Q1 25 | $717.9M | $16.6B | ||
| Q4 24 | $488.6M | $20.8B | ||
| Q3 24 | $3.4M | $15.7B | ||
| Q2 24 | $483.5M | $13.5B | ||
| Q1 24 | $420.8M | $12.4B |
毛利率CORMETA
| Q4 25 | 3.6% | 81.8% | ||
| Q3 25 | 3.5% | 82.0% | ||
| Q2 25 | 3.6% | 82.1% | ||
| Q1 25 | 4.1% | 82.1% | ||
| Q4 24 | 3.1% | 81.7% | ||
| Q3 24 | 3.2% | 81.8% | ||
| Q2 24 | 3.2% | 81.3% | ||
| Q1 24 | 3.7% | 81.8% |
营业利润率CORMETA
| Q4 25 | 0.9% | 41.3% | ||
| Q3 25 | 0.0% | 40.1% | ||
| Q2 25 | 1.1% | 43.0% | ||
| Q1 25 | 1.4% | 41.5% | ||
| Q4 24 | 0.9% | 48.3% | ||
| Q3 24 | 0.2% | 42.7% | ||
| Q2 24 | 0.9% | 38.0% | ||
| Q1 24 | 0.8% | 37.9% |
净利率CORMETA
| Q4 25 | 0.7% | 38.0% | ||
| Q3 25 | -0.4% | 5.3% | ||
| Q2 25 | 0.9% | 38.6% | ||
| Q1 25 | 1.0% | 39.3% | ||
| Q4 24 | 0.6% | 43.1% | ||
| Q3 24 | 0.0% | 38.7% | ||
| Q2 24 | 0.7% | 34.5% | ||
| Q1 24 | 0.6% | 33.9% |
每股收益（稀释后）CORMETA
| Q4 25 | $2.87 | $8.87 | ||
| Q3 25 | $-1.74 | $1.05 | ||
| Q2 25 | $3.52 | $7.14 | ||
| Q1 25 | $3.68 | $6.43 | ||
| Q4 24 | $2.50 | $7.96 | ||
| Q3 24 | $0.04 | $6.03 | ||
| Q2 24 | $2.42 | $5.16 | ||
| Q1 24 | $2.09 | $4.71 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.8B | $81.6B |
| 总债务越低越好 | $7.9B | $58.7B |
| 股东权益账面价值 | $1.9B | $217.2B |
| 总资产 | $78.4B | $366.0B |
| 负债/权益比越低杠杆越低 | 4.15× | 0.27× |
8季度趋势，按日历期对齐
现金及短期投资CORMETA
| Q4 25 | $1.8B | $81.6B | ||
| Q3 25 | $4.4B | $44.4B | ||
| Q2 25 | $2.2B | $47.1B | ||
| Q1 25 | $2.0B | $70.2B | ||
| Q4 24 | $3.2B | $77.8B | ||
| Q3 24 | $3.1B | $70.9B | ||
| Q2 24 | $3.3B | $58.1B | ||
| Q1 24 | $2.1B | $58.1B |
总债务CORMETA
| Q4 25 | $7.9B | $58.7B | ||
| Q3 25 | $7.7B | — | ||
| Q2 25 | $8.2B | — | ||
| Q1 25 | $7.9B | — | ||
| Q4 24 | $8.1B | $28.8B | ||
| Q3 24 | $4.4B | $28.8B | ||
| Q2 24 | $4.7B | — | ||
| Q1 24 | $5.2B | — |
股东权益CORMETA
| Q4 25 | $1.9B | $217.2B | ||
| Q3 25 | $1.5B | $194.1B | ||
| Q2 25 | $2.0B | $195.1B | ||
| Q1 25 | $1.0B | $185.0B | ||
| Q4 24 | $226.6M | $182.6B | ||
| Q3 24 | $645.9M | $164.5B | ||
| Q2 24 | $925.2M | $156.8B | ||
| Q1 24 | $1.1B | $149.5B |
总资产CORMETA
| Q4 25 | $78.4B | $366.0B | ||
| Q3 25 | $76.6B | $303.8B | ||
| Q2 25 | $74.0B | $294.7B | ||
| Q1 25 | $71.2B | $280.2B | ||
| Q4 24 | $69.1B | $276.1B | ||
| Q3 24 | $67.1B | $256.4B | ||
| Q2 24 | $66.8B | $230.2B | ||
| Q1 24 | $63.9B | $222.8B |
负债/权益比CORMETA
| Q4 25 | 4.15× | 0.27× | ||
| Q3 25 | 5.08× | — | ||
| Q2 25 | 4.16× | — | ||
| Q1 25 | 7.76× | — | ||
| Q4 24 | 35.96× | 0.16× | ||
| Q3 24 | 6.79× | 0.18× | ||
| Q2 24 | 5.11× | — | ||
| Q1 24 | 4.85× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-2.3B | $36.2B |
| 自由现金流经营现金流 - 资本支出 | $-2.4B | $14.8B |
| 自由现金流率自由现金流/营收 | -2.8% | 24.8% |
| 资本支出强度资本支出/营收 | 0.1% | 35.7% |
| 现金转化率经营现金流/净利润 | -4.12× | 1.59× |
| 过去12个月自由现金流最近4个季度 | $3.6B | $46.1B |
8季度趋势，按日历期对齐
经营现金流CORMETA
| Q4 25 | $-2.3B | $36.2B | ||
| Q3 25 | $3.1B | $30.0B | ||
| Q2 25 | $109.2M | $25.6B | ||
| Q1 25 | $3.4B | $24.0B | ||
| Q4 24 | $-2.7B | $28.0B | ||
| Q3 24 | $1.0B | $24.7B | ||
| Q2 24 | $2.5B | $19.4B | ||
| Q1 24 | $-878.4M | $19.2B |
自由现金流CORMETA
| Q4 25 | $-2.4B | $14.8B | ||
| Q3 25 | $2.9B | $11.2B | ||
| Q2 25 | $-74.0M | $9.0B | ||
| Q1 25 | $3.2B | $11.1B | ||
| Q4 24 | $-2.8B | $13.6B | ||
| Q3 24 | $818.1M | $16.5B | ||
| Q2 24 | $2.4B | $11.2B | ||
| Q1 24 | $-991.2M | $12.8B |
自由现金流率CORMETA
| Q4 25 | -2.8% | 24.8% | ||
| Q3 25 | 3.4% | 21.8% | ||
| Q2 25 | -0.1% | 19.0% | ||
| Q1 25 | 4.3% | 26.2% | ||
| Q4 24 | -3.5% | 28.0% | ||
| Q3 24 | 1.0% | 40.6% | ||
| Q2 24 | 3.2% | 28.7% | ||
| Q1 24 | -1.4% | 35.2% |
资本支出强度CORMETA
| Q4 25 | 0.1% | 35.7% | ||
| Q3 25 | 0.3% | 36.7% | ||
| Q2 25 | 0.2% | 34.8% | ||
| Q1 25 | 0.2% | 30.6% | ||
| Q4 24 | 0.1% | 29.8% | ||
| Q3 24 | 0.2% | 20.3% | ||
| Q2 24 | 0.2% | 20.9% | ||
| Q1 24 | 0.2% | 17.6% |
现金转化率CORMETA
| Q4 25 | -4.12× | 1.59× | ||
| Q3 25 | — | 11.07× | ||
| Q2 25 | 0.16× | 1.39× | ||
| Q1 25 | 4.67× | 1.44× | ||
| Q4 24 | -5.56× | 1.34× | ||
| Q3 24 | 295.80× | 1.58× | ||
| Q2 24 | 5.12× | 1.44× | ||
| Q1 24 | -2.09× | 1.56× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
COR
| US Healthcare Solutions | $76.2B | 89% |
| Alliance Healthcare | $6.5B | 8% |
| Animal Health | $1.5B | 2% |
| Other Healthcare Solutions | $1.1B | 1% |
| Other Non Strategic Businesses | $657.6M | 1% |
META
| Advertising | $58.1B | 97% |
| Reality Labs | $955.0M | 2% |
| Service Other | $801.0M | 1% |
